Results 1 - 9 of 9
Exelixis and Glaxo Begin Their Goodbyes
Sometimes, even the best couples break up.
A Little Bit of Cash for ArQule
ArQule receives a milestone payment from a partner.
WuXi signs more drug development deals and buys a U.S. manufacturing services company.
The pharmaceutical issues guidance for the coming year.
Talking With a Development-Stage Pharma
An interview with development-stage drugmaker Pharmacopeia.
A Bird in the Hand for Exelixis
Exelixis raises cash by selling expensive mice.
The small pharmaceutical firm signs another big deal.
Pharmacopeia presents at an investors' conference.
Speculative? Sure. But they all have intriguing compounds in development.
Results 1 - 9 of 9
Legal Information © 1995 - 2009 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK